The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.
Related to this article
Telehealth transplant consults help patients with multiple myeloma overcome racial, age, and rural barriers, speeding eligibility screening and expanding access to specialists.
Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
2
Prostate and Rare Cancer Agents Nab FDA Fast Track Status
3
Dr Bazhenova on Taletrectinib Label Update and Subgroup Data in ROS1+ NSCLC
4
FDA Approves Adjuvant Atezolizumab Plus Chemo for dMMR Colon Cancer
5